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Abstract
Background: Metadherin (MTDH) has been demonstrated as a potentially crucial mediator of various types of human
malignancies. However, the expression and role of MTDH in diffuse large-B-cell lymphoma (DLBCL) have not been reported
yet. This study aimed to illuminate the role of MTDH in the pathogenesis of DLBCL.
Methodology/Principal Findings: A remarkable elevation of MTDH on mRNA level was detected in DLBCL tissues by
quantitative polymerase chain reaction (PCR). Using Western-blot analysis we found that the expression of MTDH protein
was significantly upregulated in DLBCL cell lines and DLBCL tissues compared with peripheral blood mononuclear cells
(PBMCs) from healthy samples and tissues from patients of reactive hyperplasia of lymph node. The results showed high
expression of MTDH in 23 of 30 (76.67%) DLBCL tissues by using immunohistochemical analysis and the over expression of
MTDH was strongly correlated to the clinical staging of patients with DLBCL (P,0.05). Furthermore, the finding suggested
that the increase of MTDH in DLBCL cells could distinctly enhance cell proliferation and inhibit cell apoptosis; meanwhile,
inhibition of MTDH expression by specific siRNA clearly enhanced LY8 cell apoptosis. Upregulation of MTDH elevated the
protein level of total b-catenin and translocation of b-catenin to the nucleus directly or indirectly. Knockdown of MTDH
decreased the level of total, cytoplasmic b-catenin and reduced nuclear accumulation of b-catenin protein. This indicated
that the function of MTDH on the development of DLBCL was mediated through regulation of Wnt/b-catenin signaling
pathway.
Conclusions/Significance: Our results suggest that MTDH contributes to the pathogenesis of DLBCL mediated by activation
of Wnt/b-catenin pathway. This novel study may contribute to further investigation on the useful biomarkers and potential
therapeutic target in the DLBCL patients.
Citation: Ge X, Lv X, Feng L, Liu X, Gao J, et al. (2012) Metadherin Contributes to the Pathogenesis of Diffuse Large B-cell Lymphoma. PLoS ONE 7(6): e39449.
doi:10.1371/journal.pone.0039449
Editor: Jun Li, Sun Yat-sen University Medical School, China
Received December 6, 2011; Accepted May 21, 2012; Published June 29, 2012
Copyright:  2012 Ge et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the grants from the Natural Science Foundation of Shandong Province, China (No.Y2007C053 and No.ZR2009CM059) and
the Project of Scientific and Technological Development of Shandong Province, China (No. 2007GG10002008) to Prof. Xin Wang. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: xinwang55@yahoo.com.cn
Introduction
Diffuse large-B-cell lymphoma (DLBCL) is an aggressive
malignancy of mature B lymphocytes and is the most common
type of lymphoma in adults [1,2], accounting for 25% to 30% of
adult non-Hodgkin lymphoma in the West. It is even more
prevalent in developing countries [3,4]. DLBCL is an aggressive
disease with variable biological and cytogenetic features, as well as
clinical outcomes. About 40% of patients with DLBCL achieve
long-term survival after anthracycline-based chemotherapy [5].
However more intensive chemotherapy were failed to demonstrate
additional benefits because of more toxicity [6]. In the past few
years remarkable progress has been made in understanding the
biological heterogeneity of DLBCL and in improving survival for
DLBCL patients with combinations of chemotherapy and
immunotherapy. The introduction of antilymphoma monoclonal
antibodies, notably rituximab, in combination with chemotherapy
has significantly improved survival outcomes of patients with
DLBCL [7,8]. Nevertheless it is still fatal in the half of patients [9].
Most lymphoma probably activates more than one survival
signaling pathway; therefore, clinical studies should be promoted
with combination of multiple molecular targeted agents. The use
of single agent will result in a tolerant process where the tumor
cells will develop the signaling pathways not currently inhibited.
The development of biomarkers, which are able to select patients
who will respond to one or several of these targeted therapies, is
important too [10]. In view of this miserable illustration, further
investigating specific biomarkers and cellular signaling pathways,
understanding molecular pathogenesis of DLBCL and developing
more targeted and effective treatments are indispensable for
significantly increasing the survival and alleviating the suffering of
patients.
Metadherin (MTDH, also known as astrocyte elevated gene-1/
AEG-1 and Lyric) was first cloned as an HIV- and TNF-a–
inducible gene in primary human fetal astrocytes (PHFAs) [11,12].
Human MTDH encodes a 582-amino acid protein with a pre-
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frequently detect multiple proteins with molecular weights ranging
from 75–80 kDa to 20 kDa, possibly due to alternative splicing
and/or posttranslational modification [12–14]. In recent years,
MTDH, involved in aberrant proliferation, survival, and increased
migration, invasiveness, and metastasis of tumor cells, has been
demonstrated as a potentially crucial mediator of various types of
human malignancies. Expression analysis revealed that MTDH
expression is significantly higher in melanoma, breast, esophageal,
gastric, hepatocellular, endometrial and prostate cancers, renal cell
carcinoma, neuroblasoma and malignant glioma cell lines
compared with their normal counterparts [12,15–23]. These
observations in cell lines have been confirmed in tumor samples of
patients mainly by immunohistochemistry or gene expression
profiling [15,16,18–27]. MTDH promotes tumor progression by
modulating multiple oncogenic signaling pathways, such as NF-
kB, PI3K/Akt and Wnt/b-catenin pathways [28,29]. In HeLa
cells and human malignant glioma cells treated with tumor
necrosis factor-a (TNF-a, which induces MTDH overexpression),
MTDH translocates into the nucleus where it interacts with the
p65 subunit of NF-kB and upregulates NF-kB-induced gene
expression [29,30]. IL-8, one of NF-kB downstream genes,
positively regulated angiogenesis and metastasis and inhibition of
NF-kB blocked MTDH-mediated anchorage-independent growth
and invasion by HeLa cells [29]. A second signaling pathway
regulated by MTDH is PI3K/Akt pathway. Interestingly, this
pathway is not only activated by MTDH but also plays an
important role in regulating MTDH expression [31]. MTDH
overexpression promotes phosphorylation of Akt and GSK3b
[32], and affects many additional Akt downstream genes that are
crucial for cellular proliferation, survival and apoptosis. MTDH
knockdown induces apoptosis of prostate cancer cells through the
attenuation of Akt activity and upregulation of FOXO3a activity
[18]. More recently, MTDH has been found to connect with
Wnt/b-catenin pathway in hepatocellular carcinoma cells through
the activation of the Raf/MEK/MAPK branch of Ras signaling
pathway, leading to b-catenin nuclear translocation and upregula-
tion of different target gene expressions [16]. Inhibition of MTDH
expression by specific siRNA clearly decreased the level of b-
catenin and it may play a role in Wnt/b-catenin-mediated gastric
cancer progression [15]. These findings demonstrate that MTDH
is both a potentially biomarker of tumor malignancy and a crucial
integration factor of multiple oncogenic signaling pathways. Wnt/
b-catenin signaling pathway not only acts a significant part in
embryonic development and in maintenance of organs and tissues
in adults [33,34] but also involves in the pathogenesis of a range of
disease including many kinds of carcinomas [35]. Wnt/b-catenin
pathway plays an important role in progression of several subtypes
of lymphoma such as Epstein-Barr Virus (EBV) -positive Burkitt’s
lymphoma (BL) [36], mantle cell lymphoma (MCL) [37,38],
cutaneous lymphoma [39], extranodal marginal zone lymphoma
[40], DLBCL [41,42,43], among others [44,45]. Since aberrant
activation of Wnt/b-catenin pathway is probably important for
lymphoma development and progression including DLBCL, we
hypothesize that MTDH is in close contact with Wnt/b-catenin
pathway in DLBCL and contributes to the pathogenesis of
DLBCL.
For the first time, our present manuscript focuses on illuminat-
ing the role of MTDH and the relationship between MTDH and
Wnt/b-catenin pathway in the pathogenesis of DLBCL. We
demonstrate the overexpression of MTDH and b-catenin in
DLBCL and the effect of MTDH expression on biological
behavior of DLBCL cell lines. We also provide evidences for the
link between MTDH and Wnt/b-catenin pathway in DLBCL.
Results
MTDH is Overexpressed in DLBCL
Expression of MTDH was detected by Western blot, with the
single band size of 75 kDa, in peripheral blood mononuclear cells
(PBMCs) from healthy samples, human DLBCL cell lines LY1 and
LY8, and MCL cell lines Jeko-1, Mino, and SP53. The protein
level of MTDH was much lower in PBMCs from healthy samples
compared with all the human DLBCL and MCL cell lines
(Figure 1A). Moreover MTDH was found in the nuclear fractions,
and possibly also in the cytoplasmic fractions, in both 2 DLBCL
cell lines (Figure 1B). To examine whether the expression of
MTDH in DLBCL tissues is clinically correlated with DLBCL
pathogenesis, comparative analysis of MTDH expression was
conducted on patient samples and inflammatory lymph node
tissues through real-time quantitative PCR, immunohistochemis-
try and Western blot. MTDH mRNA was found to be
differentially overexpressed in DLBCL samples, whereas it was
weakly expressed in reactive hyperplasia of lymph node tissues
(P,0.0001, Figure 2A). Western blot analysis revealed that
DLBCL exhibited significantly higher levels of MTDH protein
expression compared to levels in their counterparts (P,0.0001,
Figure 2B).
To further determine whether MTDH protein overexpression is
associated with clinicopathological characteristics of DLBCL,
a cohort of paraffin-embedded, archived DLBCL tissues (n=30)
were examined by immunohistochemical staining with an
antibody against human MTDH. As shown in Figure 2C,
significant MTDH staining was observed in DLBCL samples,
while only little or rather non-expression of MTDH was detected
in the 15 reactive hyperplasia of lymph node tissues (Figure 2D).
Among the 30 DLBCL samples, only 7 negative for MTDH and
the remaining 23 (76.67%) showed variable levels of MTDH.
MTDH expression was detected predominantly in the cytoplasm
and occasionally in the nucleus. Taken together, these observa-
Figure 1. MTDH and b-catenin are overexpressed and nucleic
localization in DLBCL cell lines. (A) Expression of MTDH (75 kDa)
and b-catenin (94 kDa) were detected in the indicated cell lines. PBMCs
represent peripheral blood mononuclear cells from healthy samples.
Expression of b-actin was used as loading control. (B) Subcellular
protein fractionation using the cell lysates of 2 DLBCL cell lines revealed
that MTDH and b-catenin were localized in the nucleus (N) and possibly
also in the cytoplasm (C) and. The expression of b-actin in the
cytoplasm and H3 in the nucleus served as controls for the efficiency of
subcellular fractionation.
doi:10.1371/journal.pone.0039449.g001
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pathogenesis of DLBCL.
Relationship between MTDH Upregulation and the
Clinicopathological Characteristics of DLBCL
Statistical analyses were done to examine the correlation
between the expression of MTDH protein by immunohistochem-
istry analysis and the clinical features of DLBCL. As shown in
Table 1, there was no correlation between MTDH expression and
patient age (P=0.204), gender (P=1.000) or B symptoms
(P=1.000). Nevertheless, the expression of MTDH protein
analyzed by immunohistochemical staining was strongly correlated
to the clinical staging of patients with DLBCL (P,0.05), which
was further confirmed by the Spearman rank correlation analysis.
Spearman correlation of MTDH expression to clinical staging was
0.507 (P=0.004). Together, these results indicate that the
overexpression of MTDH is associated with DLBCL clinical
progression.
Induction of MTDH Enhances Proliferation and Inhibits
Apoptosis of DLBCL Cells and Knockdown of MTDH
Reinforces Apoptosis of DLBCL Cells
It is previously reported that TNF-a up-regulates MTDH
expression at both the mRNA and protein level in the human
cervical carcinoma cell line HeLa [29]. To verify the effect of
TNF-a on MTDH expression in DLBCL cells, the protein level of
MTDH in LY1 and LY8 cell lines was determined by using
Western blot analysis after treatment with TNF-a for 48 hours
(final concentration 250 pg/ml). As shown in Figure 3A, the
expression of MTDH was up-regulated about 20% at the protein
Figure 2. MTDH is overexpressed in DLBCL tumor samples. (A) Real-time quantitative PCR analysis of MTDH expression in DLBCL (n=21) and
control (n=25). PCR products were confirmed as a single product at the desired size on agarose gels (1–3: DLBCL; 4–5: Control). Control, reactive
hyperplasia of lymph node. b-actin was used as a loading control. (B) Expression of MTDH protein (75 kDa) in DLBCL (1–3) and reactive hyperplasia of
lymph node tissues (4–6). Expression levels were normalized with b-actin. (C) Detection of MTDH expression in DLBCL by IHC. (D) Detection of MTDH
expression in reactive hyperplasia of lymph node by IHC. Original magnification, 6400. Points indicate mean of triplicate determinations, bars, SD.
****p,0.0001 versus control.
doi:10.1371/journal.pone.0039449.g002
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DLBCL cells were exposed to TNF-a for further studies
investigating the potential functions of MTDH in these cells.
The effect of MTDH on the proliferation of LY1and LY8 cell lines
was accessed with
3H-TdR incorporation assay. The increase of
MTDH could promote the proliferation of 2 DLBCL cell lines
(P,0.05, Figure 3B). To determine whether the enhancing
proliferation of LY1 and LY8 cells due to upregulation of MTDH
was associated with the apoptosis of these cells, the effect of
MTDH on the apoptosis of LY1 and LY8 was analyzed using
Annexin V-FITC/PI staining followed by flow cytometry
(Figure 3C). Cell apoptosis was inhibited after MTDH over-
expression by exposure (48 hours) to TNF-a at the indicated
concentration in comparison with untreated cells (P,0.05).
To further investigate the potential function of MTDH gene in
DLBCL pathogenesis, cell apoptosis was evaluated in MTDH
knockdown cells (Figure S1). As shown in Figure 4, MTDH
knockdown cells exhibited significantly higher apoptotic rate in
comparison to the cells transfected with negative control siRNA
(P,0.05).
Between the LY8 cells untreated and treated with TNF-a and
siRNA towards MTDH, there was little change in their apoptosis
rate when the expression of MTDH was detected to be unchanged
(Figure 5A, P.0.05). Besides, the cells treated with TNF-a and
control siRNA showed lower apoptosis rate than the cells treated
with TNF-a and MTDH siRNA (Figure 5A, P,0.05). This
probably showed that the effect on the proliferation and apoptosis
occurred after the expression change of MTDH rather than
directly after TNF-a treatment. Taken together, these results
suggested that MTDH could promote cell apoptosis and was
essential for the proliferation in DLBCL cells, so that it probably
plays a key role in the pathogenesis of DLBCL.
Nuclear Localization of b-catenin in DLBCL Cells
To determine the activity of Wnt/b-catenin pathway in
DLBCL, we presently assessed the expression of b-catenin, the
chief downstream effector of Wnt/b-catenin pathway, in 2
DLBCL, 3 MCL cell lines. As illustrated in Figure 1A, the protein
level of b-catenin was distinctly higher in the human DLBCL and
MCL cell lines compared with PBMCs from healthy samples.
Furthermore, since b-catenin is a transcription factor that migrates
to the nucleus and mediates the activation of Wnt/b-catenin
pathway [37], we assessed its nuclear localization. Making use of
subcellular protein fractionation and Western blot, b-catenin was
detected in the nuclear lysates, and possibly also in the cytoplasmic
lysates, in 2 DLBCL cell lines (Figure 1B). The expression of b-
actin in the cytoplasm and H3 in the nucleus served as controls for
the efficiency of subcellular protein fractionation.
Wnt/b-catenin Pathway is One of the Downstream
Signalings Activated by MTDH in DLBCL
Since Wnt/b-catenin pathway was found to be aberrant in
DLBCL cells and is probably involved in the pathogenesis of
DLBCL, we focused on discussing whether Wnt/b-catenin
pathway is overactivated by MTDH using western blot analysis.
Total b-catenin protein level was increased in TNF-a-treated cells
(P,0.05, Figure 6A). The transcriptional activity of b-catenin
requires its nuclear migration of b-catenin [37], therefore we
checked the localization of b-catenin with subcellular protein
fractionation and Western blot analysis. In the TNF-a untreated
DLBCL cells b-catenin was localized both in the cytoplasm and
the nucleus as described previously. After treatment with TNF-a,
the protein level of nuclear b-catenin was elevated in the
meantime (P,0.05, Figure 6B) following MTDH upregulation.
To more immediately study the relationship between MTDH
and Wnt/b-catenin signaling in DLBCL, we examined the
expression of b-catenin in LY8 cells infected with MTDH-RNAi
lentivirus or negative control lentivirus. The protein level of total
b-catenin was decreased in MTDH-siRNA-treated cells
(Figure 7A, P,0.01). At the same time, MTDH knockdown
destabilized b-catenin protein and then resulted in a decrease in
both cytoplasmic (Figure 7B, P,0.01) and nuclear b-catenin levels
(Figure 7C, P,0.05).
Table 1. Correlation between MTDH expression by immunochemistry analysis and the clinicopathological characteristics of DLBCL
patients.
Characteristics MTDH expression Fisher’s Exact Test P value
Negative no.(%) Positive no.(%)
Age(years)
,60 2 (12.5) 14 (87.5) 0.204
.60 5 (35.7) 9 (64.3)
Gender
Male 5 (22.7) 17 (77.3) 1.000
Female 2 (25.0) 6 (75.0)
Clinical stage
I 4 (57.1) 3 (42.9) 0.047
II 2 (28.6) 5 (71.4)
III 1 (20.0) 4 (80.0)
IV 0 (0.0) 11(100.0)
B symptoms
Yes 3 (23.1) 10 (76.9) 1.000
No 4 (23.5) 13 (76.5)
doi:10.1371/journal.pone.0039449.t001
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siRNA towards MTDH, there was almost no change of b-catenin
expression when the expression of MTDH was detected to be
unchanged (Figure 5B, P.0.05). However, the protein level of
total b-catenin was increased in the cells treated with TNF-a and
control siRNA compared with the cells treated with TNF-a and
MTDH siRNA (Figure 5B, P,0.05). The result probably
suggested that the influence on b-catenin occurred after the
expression change of MTDH rather than directly after TNF-
a treatment.
These findings indicate that MTDH upregulation could directly
or indirectly increase the protein level of b-catenin in the nucleus
and thus play a significant part as an upstream activator for Wnt/
b-catenin signaling pathway.
Discussion
In recent years MTDH has been demonstrated as a potentially
crucial mediator of various types of human malignancies. Its
expression is significantly higher in melanoma, breast, esophageal,
gastric, hepatocellular and prostate cancers, renal cell carcinoma,
neuroblasoma and malignant glioma cell lines compared with their
normal counterparts [12,15–23]. These observations in cell lines
have been confirmed in tumor patient specimens [15,16,18–27].
In the present manuscript we report that MTDH is highly
Figure 3. Upregulation of MTDH enhances proliferation and inhibits apoptosis of DLBCL cells. (A) LY1 and LY8 cells were either
untreated or treated with 250 pg/mL of TNF-a for 48 hours. The expression of MTDH protein was analyzed by Western blot. (B) DLBCL cells were
treated with TNF-a at the indicated concentration for 48 hours, and cell proliferation was determined by 3H-TdR incorporation assay. Columns
indicate mean of triplicate determinations; bars, SD. (C) LY1(left panel) and LY8(right panel) cells were treated with TNF-a (250 pg/mL for 48 hours)
and cell apoptosis was detected by flow cytometer. Early apoptotic cells were defined as Annexin-V-FITC-positive, PI-negative cells. Columns indicate
mean of triplicate determinations; bars, SD. *p,0.05 versus control.
doi:10.1371/journal.pone.0039449.g003
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first time. Our studies demonstrate that MTDH is overexpressed
at both the mRNA and protein levels in DLBCL cell lines as well
as DLBCL tissues. Besides, 76.67% (23/30) DLBCL samples
showed upregulation of MTDH analyzed by immunohistochem-
ical staining, while only little or rather non-expression of MTDH
was detected in reactive hyperplasia of lymph node tissues. Further
statistical analysis of the relationship between MTDH staining and
the clinical features of DLBCL patients suggests that the over
expression of MTDH is strongly correlated to the clinical staging
of patients with DLBCL, whereas it is not correlated with the age,
gender or B symptoms.
Studies are ongoing to further clarify the biological impact of
MTDH overexpression on DLBCL tumor cells, in which we
investigated gain-of-function through MTDH upregulation in-
duced by TNF-a and loss-of-function through MTDH knockdown
by small interfering RNA in DLBCL cells. We observed that the
upregulation of MTDH in DLBCL cells could promote cell
proliferation, which is in accordance with the inhibitory effect on
cell apoptosis. Considering the possibility that the effect on the
proliferation and apoptosis occurs directly after TNF-a treatment,
we treated the cell lines with TNF-a and control siRNA or siRNA
towards MTDH simultaneously and detected the apoptosis rate
and b-catenin expression. The results suggested that there was
almost no change of apoptosis rate and b-catenin expression
between treated and untreated cells when the expression of
MTDH was detected to be unchanged. However, cell apoptosis
was inhibited and the protein level of total b-catenin was increased
in the cells treated with TNF-a and control siRNA compared with
the cells treated with TNF-a and MTDH siRNA. This probably
suggested that the effect on the cell biological behavior and Wnt/
b-catenin signaling occurred after the expression change of
MTDH rather than directly after TNF-a treatment. The results
also show that the reducing of MTDH in DLBCL cells could
enhance cell apoptosis. Taken together, these data suggest that
MTDH upregulation is likely associated with the pathogenesis of
DLBCL.
Previous studies have demonstrated that MTDH promotes
tumor initiation and progression by modulating multiple down-
stream oncogenic pathways, such as NF-kB, PI3K/Akt and Wnt/
b-catenin pathways [28,29]. It is known that activation of Wnt/b-
catenin pathway is probably important for malignancy of DLBCL.
b-catenin is the central transcription factor of the Wnt/b-catenin
signaling pathway, and in certain cases it is accumulated in the
nucleus and mediates the activation of Wnt/b-catenin pathway. In
this present study, we validated the upregulation of total b-catenin
Figure 4. Knockdown of MTDH promotes apoptosis of DLBCL cells. LY8 cells were transfected with MTDH siRNA or negative control siRNA
and cell apoptosis was detected by flow cytometer. Early apoptotic cells were defined as Annexin-V-PE-positive, 7-AAD-negative cells. Columns
indicate mean of triplicate determinations; bars, SD. *p,0.05 versus control; mp.0.05 versus control.
doi:10.1371/journal.pone.0039449.g004
Role of Metadherin in the Pathogenesis of DLBCL
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39449and expression of nuclear b-catenin in DLBCL cell lines.
Moreover, our research showed that MTDH upregulation elevates
both total and nuclear b-catenin protein. The higher amount of b-
catenin found in the nucleus could be a consequence of the
increase in the total level of the protein or due to a specific role of
MTDH in the translocation of b-catenin. That is to say MTDH
upregulation promotes translocation of b-catenin to the nucleus
directly or indirectly. In contrast, we showed the reduction of total,
cytoplasmic and nuclear b-catenin protein induced by MTDH
silencing, which revealed the close relationship between MTDH
and Wnt/b-catenin pathway. These results indicate that MTDH
plays a significant role as an upstream activator for Wnt/b-catenin
signaling pathway in DLBCL. Recent studies illuminated that
MTDH can activate Wnt/b-catenin signaling pathway via
ERK42/44 activation, which then leads to GSK3b phosphoryla-
tion, and thus facilitate nuclear translocation of b-catenin in
hepatocellular carcinoma [16]. In gastric cancer inhibition of
MTDH may decrease the level of b-catenin and inactivate Wnt/b-
catenin pathway through reducing phosphorylation of AKT and
glycogen synthase kinase (GSK)-3b (Ser 9) [15]. To our
knowledge, the mechanisms that MTDH actives Wnt/b-catenin
pathway are not clear, accordingly further research should be
done on the regulation of Wnt/b-catenin pathway by MTDH in
human DLBCL. Scientists have revealed that some agents could
lead to apoptosis or suppress the growth of lymphoma cells
through Wnt/b-catenin signaling pathway [41,44]. In addition, in
two rituximab responsive DLBCL cell lines rituximab could affect
the expression of genes in classical signaling cascades, including
Wnt pathway, among others [42]. Since MTDH not only involves
in the pathogenesis of DLBCL itself but also plays a significant role
as an upstream activator for Wnt/b-catenin signaling pathway,
there is great potential that can act as a therapeutic target of
DLBCL.
In summary, our findings suggest that the over expression of
MTDH is associated with the pathogenesis of DLBCL for the first
time. We demonstrate that MTDH was markedly overexpressed in
both DLBCL cell lines and tissues and b-catenin was upregulated,
with its nuclear localization, in DLBCL cell lines compared with
their counterparts. We found that the over expression of MTDH
was strongly correlated to the clinical staging of patients with
DLBCL. Furthermore, we determined that apoptosis of DLBCL
cell lines was distinctly inhibited while cell proliferation was
enhanced according with MTDH upregulation after treatment
with TNF-a. Cell apoptosis was also promoted in MTDH
knockdown cells in comparison to those transfected with negative
control siRNA. Moreover, MTDH promotes growth and survival
of DLBCL cells via regulating Wnt/b-catenin signaling pathway.
The upregulation of MTDH induced by TNF-a could increase the
protein level of total b-catenin and its nuclear translocation
directly and indirectly, whereas, MTDH silencing could reduce
the level of total b-catenin protein, facilitate the degradation of
cytoplasmic b-catenin and decrease its nuclear translocation.
Further efforts are needed to expound the particular molecular
mechanism of MTDH upregulating Wnt/b-catenin pathway and
understand the roles of MTDH in DLBCL development, which
may enable MTDH to be a useful biomarker and potential
therapeutic target for DLBCL.
Materials and Methods
Patient and Samples
Paraffin-embedded archived samples, including thirty cases of
DLBCL diagnosed between January 2008 and December 2010
according to the WHO criteria [46], and fifteen reactive
hyperplasia of lymph node tissues, were collected from the
Shandong Provincial Hospital. Twenty-one biopsies of DLBCL
tissues and twenty-five tissues from patients of reactive hyperplasia
of lymph node were frozen and stored in liquid nitrogen until
further use. Peripheral blood mononuclear cells (PBMCs) from
healthy volunteers served as normal control compared with
human DLBCL cell lines LY1 and LY8. Peripheral blood was
collected by heparin anticoagulation and PBMCs were separated
using the Ficoll-Hypaque gradient centrifugation method. The
Figure 5. Combined action of TNF-a treatment and siRNA
towards MTDH. (A) LY8 cells transfected with control siRNA and
MTDH siRNA were either untreated or treated with 250 pg/mL of TNF-
a for 48 hours. Then cell apoptosis was detected by flow cytometer. (B)
Detection of total b-catenin proteins by Western blot analysis in
transfected LY8 cell line untreated and treated with TNF-a at the
indicated concentration and exposure time. Data expressed as
mean6SD. *p,0.05 versus control; mp.0.05 versus control.
doi:10.1371/journal.pone.0039449.g005
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Ethics Committee and written informed consent was obtained
from all participants involved in this study.
Cell Lines and Cell Culture
All cell lines were maintained at 37uC in 5% carbon dioxide.
The human DLBCL cell lines LY1 and LY8 were cultured in
Iscove’s Modified Dulbecco’s Medium (IMDM; Hyclone, Logan,
UT, USA) supplemented with 10% fetal bovine serum (FBS,
HyClone, Logan, UT, USA) [47]. The 3 human MCL cell lines,
Jeko-1,Mino,and SP53, were maintained in RPMI 1640 medium
with L-glutamine (Hyclone, Logan, UT, USA), penicillin (100 U/
mL), streptomycin (100 mg/mL) and 10%FBS as previously
described [48].
Antibodies and Reagents
Rabbit anti-MTDH polyclonal antibody was purchased from
Invitrogen (Carlsbad, CA, USA). Rabbit anti-b-catenin polyclonal
antibody and mouse anti-b-actin monoclonal antibody was from
Abcam (Cambridge, MA). Rabbit anti-histone 3 (H3) polyclonal
antibody was obtained from Beyotime (Shanghai, China).
3H-
thymidine was purchased from Perkin-Elmer (Waltham, MA).
TNF-a was purchased from PeproTech (Rocky Hill, NJ, USA).
For studies, it was dissolved in 0.1% of BSA and aliquoted as
a stock solution. To prepare working solutions, aliquots were
further diluted in Iscove’s modified Dulbecco’s medium (IMDM;
Hyclone, Logan, UT, USA) supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Hyclone, Logan, UT, USA)
immediately before each experiment.
Knockdown of Human MTDH by RNA Interference (RNAi)
RNAi target sequence to human MTDH gene was 59-
AACAGAAGAAGAAGAACCGGA-39 by reference to the pre-
vious study [31]. The sequences of small interfering RNA (siRNA)
targeting the human MTDH gene and negative control siRNA
were cloned into the pGCL-GFP and generated using stable
lentivirus expression vectors by Shanghai GeneChem. LY8 cells
were plated in 96-well plates (10
4cells/well) and were infected with
MTDH-RNAi lentivirus or negative control lentivirus with the
multiplicity of infection (MOI) 80 according to the manufacturer’s
instructions. The medium was changed with fresh medium after
8–12 hours. Infection efficiencies were determined by GFP
fluorescence. The cells were then harvested for mRNA and
protein extraction or detection of cell apoptosis. In addition, the
Figure 6. MTDH mediated aberrant activation of Wnt/b-catenin pathway in DLBCL cells. (A) Detection of total b-catenin proteins by
Western blot analysis in LY1 and LY8 cell lines untreated and treated with TNF-a at the indicated concentration and exposure time. (B) Analysis of
nuclear b-catenin protein expression using subcellular fractionation and Western blot. The expression o f b-actin in the cytoplasm(C) and H3 in the
nucleus (N) served as controls for the efficiency of subcellular fractionation. Data expressed as mean6SD. *p,0.05 versus control.
doi:10.1371/journal.pone.0039449.g006
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hours (final concentration 250 pg/ml) and then harvested for
protein extraction and detection of cell apoptosis.
Reverse Transcription-Polymerase Chain Reaction (PCR)
and Real-time Quantitative PCR
Total RNA was extracted from tissues using Trizol (Invitrogen).
Then reverse transcription reaction was conducted by means of
TaKaRa reverse transcription reagents (TaKaRa, Dalian, China).
The reaction was incubated at 37uC for 15 minutes, and 85uC for
5 seconds. Amplification reactions were performed using SYBR
Premix Ex Taq (Perfect Real Time) (TaKaRa, Dalian, China) on
ABI 7500 Real-Time quantitative PCR System with cycling as
follows: an initial cycle for 2 minutes at 95uC, followed by 40 bi-
phasic cycles of 15 seconds at 95uC and 1 minute at 60uC. PCR
products were confirmed as a single product at the desired size on
Figure 7. MTDH downregulation inhibits the activity of Wnt/b-catenin pathway in DLBCL cells. (A) Analysis of total b-catenin protein by
Western blot analysis in LY8 cells transfected with negative control siRNA and MTDH siRNA. (B) and (C) Expression of cytoplasmic(B) and nuclear (C) b-
catenin protein was analyzed in LY8 cells. The expression of b-actin in the cytoplasm and H3 in the nucleus served as controls for the efficiency of
subcellular fractionation. Data expressed as mean6SD. *p,0.05 versus control; **p,0.01 versus control; mp.0.05 versus control.
doi:10.1371/journal.pone.0039449.g007
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primers for RT-PCR were obtained from Biosune (Shanghai,
China), and the primer sequences are listed in Table 2. Expression
data were normalized to the geometric mean of housekeeping gene




Total protein was extracted from DLBCL tumors, reactive
hyperplasia of lymph node tissues, LY1, LY8, Jeko-1, Mino, SP53
cell lines and PBMCs of healthy samples using RIPA and 1%
PMSF (Shenergy Biocolor, Shanghai, China). For cytoplasmic and
nuclear extracts, cells were washed with phosphate-buffered saline
(PBS) and were lysed in NE-PER extraction reagent (Pierce)
according to the manufacturer’s protocol. The protein concentra-
tion of the samples was determined by the BCA assay (Shenergy
Biocolor). Cell lysates were then electrophoresed on 10% SDS-
polyacrylamide gels, while cytoplasmic and nuclear lysates were
electrophoresed on 12% SDS-polyacrylamide gels, and next
transferred onto nitrocellulose membranes. After the membranes
were blocked with 5% skim milk in Tris-saline buffer with 0.1%
Tween-20, they were subsequently probed with primary anti-
bodies at 4uC overnight. After washings with TBST, secondary
antibody conjugated with the horseradish peroxidase (Zhongshan
Goldenbridge, Beijing, China) was added to the membranes. After
washings with TBST, proteins were detected using the chemilu-
minescence detection kit (Millipore, Massachusmetts, USA).
Antibodies used in this study included anti-MTDH (1 mg/ml),
anti-b-catenin (1:5000), anti-b-actin (1:10000) and anti-H3 with
a dilution of 1:1000. Western blot results were analyzed using the
Las-4000 Image software and Multi Gauge Ver.3.0 software
(Fujifilm Life Science, Japan).
Immunohistochemistry Study
In brief, formalin-fixed, paraffin-embedded tissue sections of 4-
mM thickness were deparaffinized and hydrated. High-pressure
antigen retrieval was performed using citrate buffer (pH6).
Endogenous peroxidase was quenched with 3% hydrogen
peroxide in methanol for 15 minutes, followed by incubation with
normal serum to block non-specific staining. Rabbit anti-MTDH
(1:25) antibody was then incubated with the sections overnight at
in a humidified chamber 4uC; the second antibody was from SP
reagent kit (Zhongshan Goldenbridge Biotechnology Company,
Beijing, China). After washing, the tissue sections were treated
with biotinylated anti-rabbit secondary antibody, followed by
further incubation with streptavidin-horseradish peroxidase com-
plex. Stained with diaminobenzidine Kit (DAB, Zhongshan
Goldenbridge Biotechnology Company, Beijing, China), the
sections were counterstained with hematoxylin and mounted.
Immunohistochemical staining of samples and negative controls
occurred simultaneously, and the primary antibody was replaced
with PBS for negative controls.
Immunohistochemical stainings were assessed in a series of
randomly selected 5 high-power fields, which were believed to be
representative of the average in tumors at6400 magnification, by
two independent observers who were blinded to all clinical data.
The sections were scored according to the proportion of positively
stained tumor cells. Tumors displaying staining in 30% or more of
the cells were categorized as positive cases. In the meanwhile,
tumors displaying staining less than 30% of the cells were
categorized as negative cases.
Assessment of Cell Proliferation
LY1 and LY8 cell lines (5610
3, respectively) were seeded into
96-well plates, treated with TNF-a (250 pg/ml) and cultured for
48 hours.
3H-thymidine (1 mCi/well) was added into the cultures
16 hours before the end of the experiment. Then cell proliferation
was evaluated using
3H-TdR incorporation method as described
previously [49]. Triplicate wells were included in each sample.
Assessment of Cell Apoptosis
After treatment of LY1 and LY8 cells with TNF-a (250 pg/ml)
for 48 h, cell apoptosis and necrosis were determined using an
annexin V- fluorescein isothiocyanate (FITC) and propidium
iodide (PI) apoptosis detection kit (Neobioscience, Shenzhen,
China), according to the manufacturer’s instructions. Briefly, an
aliquot of 10
6 cells was incubated with annexin V-FITC and PI for
10 minutes at room temperature in the dark. Cells were then
immediately analyzed with FACScan flow cytometer (Beckman
Coulter, Chicago, USA). Viable cells are not stained with annexin
V-FITC or PI. The necrotic cells were annexin V-FITC and PI-
positive, whereas apoptotic cells were annexin V-FITC-positive
and PI-negative [50,51]. After infected with MTDH-RNAi
lentivirus or negative control lentivirus, untreated or treated with
TNF-a (250 pg/ml) for 48 hours, LY8 cell apoptosis was detected
by using an annexin V- phycoerythrin (PE) and 7-amino-
actinomycin D (7-AAD) apoptosis detection kit (MultiSciences
Biotech Co., Ltd., Hangzhou, China), according to the manu-
facturer’s instructions. Cells were also immediately detected with
FACScan flow cytometer (Beckman Coulter, Chicago, USA).
Viable cells are not stained with annexin V-PE or 7-AAD. The
necrotic cells were annexin V-PE and 7-AAD-positive, whereas
apoptotic cells were annexin V-PE-positive and 7-AAD-negative.
Statistical Analysis
All statistical analyses were performed by using the statistics
software SPSS 13.0 for Windows. The numerical data were
statistically analyzed by 2-tailed Student’s t test t-test. Fisher’s
exact test was used to analyze the relationship between the level of
MTDH expression and clinicopathological features. Bivariate
correlation between two independent variables was calculated by
Spearman’s rank correlation coefficient. Statistically significance
was defined as P,0.05.
Supporting Information
Figure S1 Infection efficiency of lentivirus and knock-
down of MTDH in DLBCL cells. (A) Infection efficiency of
lentivirus in LY8 cells. The cells were treated with MTDH-specific
lentivirus-mediated small interfering RNA (siMTDH) or with non-
targeting siRNA as a negative control (siCon). Infection efficiency
was observed by fluorescent microscopy: the upper row, bright
field photos; the lower row, green fluorescence photos (original
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mRNA by siRNA was detected using quantitative PCR. The
specific siRNA inhibited MTDH expression (p,0.05 versus
control). (C) The specific siRNA effectively suppressed MTDH
protein expression analyzed by Western blot. Expression of b-actin
was used as loading control.
(TIF)
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